Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial

被引：0
|
作者：
Ma, Lucy Xiaolu
Titmuss, Emma
Jonker, Derek J.
Kennecke, Hagen Fritz
Berry, Scott R.
Couture, Felix
Ahmad, Chaudhary E.
Goffin, John R.
Kavan, Petr
Harb, Mohammed
Colwell, Bruce
Samimi, Setareh
Samson, Benoit
Abbas, Tahir
Aubin, Francine
Koski, Sheryl L.
Tu, Dongsheng
O'Callaghan, Christopher J.
Loree, Jonathan M.
Chen, Eric Xueyu
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Genome Sci Ctr, BCCA, Vancouver, BC, Canada
[3] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[4] Oregon Hlth & Sci Univ, Portland, OR USA
[5] Queens Univ, Kingston, ON, Canada
[6] Hotel Dieu Quebec, CHU Quebec, Quebec City, PQ, Canada
[7] Eastern Hlth, St John, NF, Canada
[8] Juravinski Canc Inst, Hamilton, ON, Canada
[9] Jewish Gen Hosp Sir Mortimer B Davis Jewish Gen H, Montreal, PQ, Canada
[10] Moncton City Hosp, Moncton, NB, Canada
[11] Nova Scotia Canc Care, Halifax, NS, Canada
[12] Hosp Sacr Coeur Montreal, Montreal, PQ, Canada
[13] Hop Charles LeMoyne, St Julie, PQ, Canada
[14] Saskatchewan Canc Agcy, Saskatoon, SK, Canada
[15] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[16] Cross Canc Inst, Edmonton, AB, Canada
[17] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[18] BC Canc Vancouver, Vancouver, BC, Canada
[19] Univ Hlth Network, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3587
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
    Solar Vasconcelos, Joao Paulo
    Chen, Nan
    Titmuss, Emma
    Tu, Dongsheng
    Brule, Stephanie Y.
    Goodwin, Rachel
    Jonker, Derek J.
    Price, Timothy
    Zalcberg, John R.
    Moore, Malcolm J.
    Karapetis, Christos S.
    Siu, Lillian
    Shapiro, Jeremy
    Simes, John
    Gill, Sharlene
    O'Callaghan, Chris J.
    Loree, Jonathan M.
    CLINICAL CANCER RESEARCH, 2024, 30 (06) : 1121 - 1130
  • [32] A phase II trial to assess the impact of b2 adrenergic blockade in immune checkpoint inhibitor (ICI)- refractory metastatic triple negative breast cancer (mTNBC)
    Gandhi, Shipra
    Roy, Arya Mariam
    Minderman, Hans
    Rosario, Spencer
    Repasky, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Blood MSI dynamics as a predictive biomarker of immune checkpoint inhibitor therapy efficacy in colorectal cancer (CRC): preliminary results from an observational trial
    Byakhova, M.
    Veselovsky, E.
    Yudina, V.
    Kuznetsova, O.
    Kravchuk, D.
    Lebedeva, A.
    Belova, E.
    Taraskina, A.
    Grigoreva, T.
    Kavun, A.
    Nikulin, V.
    Mileyko, V.
    Tryakin, A.
    Fedyanin, M.
    Ivanov, M.
    VIRCHOWS ARCHIV, 2024, 485 : S422 - S422
  • [34] Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials
    Cancanelli, Luca
    Rivano, Melania
    Di Spazio, Lorenzo
    Chiumente, Marco
    Mengato, Daniele
    Messori, Andrea
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
  • [35] Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials
    Nicholls, Danielle Lilly
    Xu, Maria C.
    Zhan, Luna
    Sharma, Divya
    Hueniken, Katrina
    Chiasson, Kaitlyn
    Wahba, Mary
    Brown, M. Catherine
    Grant, Benjamin
    Shapiro, Jeremy
    Karapetis, Christos S.
    Simes, John
    Jonker, Derek
    Tu, Dongsheng
    O'Callaghan, Christopher
    Chen, Eric
    Liu, Geoffrey
    JCO CLINICAL CANCER INFORMATICS, 2025, 9
  • [36] Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.
    Vasconcelos, Joao Paulo Solar
    Chen, Nan
    Tu, Dongsheng
    Brule, Stephanie Yasmin
    Goodwin, Rachel Anne
    Jonker, Derek J.
    Price, Timothy Jay
    Zalcberg, John Raymond
    Moore, Malcolm J.
    Karapetis, Christos Stelios
    Siu, Lillian L.
    Shapiro, Jeremy David
    Simes, John
    O'Callaghan, Christopher J.
    Loree, Jonathan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 124 - 124
  • [37] Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials
    Ergun, Y.
    Kalkan, Z.
    Ileri, S.
    Tunc, S.
    Urakci, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S212 - S212
  • [38] Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
    Bradbury, Penelope A.
    Morris, Donald G.
    Nicholas, Garth
    Tu, Dongsheng
    Tehfe, Moustapha
    Goffin, John R.
    Shepherd, Frances A.
    Gregg, Richard W.
    Rothenstein, Jeffrey
    Lee, Christoper
    Kuruvilla, Sara
    Keith, Bruce D.
    Torri, Vamsee
    Blais, Normand
    Hao, Desiree
    Korpanty, Grzegorz J.
    Goss, Glenwood
    Melosky, Barbara L.
    Mates, Mihaela
    Leighl, Natasha
    Ayoub, Jean-Pierre
    Sederias, Joana
    Feilotter, Harriet
    Seymour, Lesley
    Laurie, Scott A.
    LUNG CANCER, 2018, 120 : 142 - 148
  • [39] A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial
    Jonker, Derek J.
    Tang, Patricia A.
    Kennecke, Hagen
    Welch, Stephen A.
    Cripps, M. Christine
    Asmis, Timothy
    Chalchal, Haji
    Tomiak, Anna
    Lim, Howard
    Ko, Yoo-Joung
    Chen, Eric X.
    Alcindor, Thierry
    Goffin, John R.
    Korpanty, Grzegorz J.
    Feilotter, Harriet
    Tsao, Ming S.
    Theis, Ashley
    Tu, Dongsheng
    Seymour, Lesley
    CLINICAL COLORECTAL CANCER, 2018, 17 (03) : 231 - +
  • [40] Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group
    Giessen, C.
    Graeven, U.
    Laubender, R. P.
    Modest, D. P.
    Schulz, C.
    Porschen, R.
    Schmiegel, W.
    Reinacher-Schick, A.
    Hegewisch-Becker, S.
    Stintzing, S.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 3051 - 3055
12345